Back to Search
Start Over
Nektar advances abuse‐proof opioid: Biotech firm uses PEGylation to stem euphoria effect.
- Source :
-
C&EN Global Enterprise . 7/24/2017, Vol. 95 Issue 30, p1-2. 2p. 1 Color Photograph. - Publication Year :
- 2017
-
Abstract
- The article reports on advancements in the developmental opioid NKTR-181 by biotechnology company Nektar Therapeutics. Topics include the public health goal of the company's new drug development, Phase III clinical trial on long-term safety of NKTR-181, and comments from Nektar chief scientific officer Stephen K. Doberstein.
- Subjects :
- *DRUG development
*OPIOIDS
*CLINICAL drug trials
Subjects
Details
- Language :
- English
- ISSN :
- 24747408
- Volume :
- 95
- Issue :
- 30
- Database :
- Academic Search Index
- Journal :
- C&EN Global Enterprise
- Publication Type :
- Periodical
- Accession number :
- 125270448